重组人血管内皮抑制素联合培美曲塞和顺铂治疗晚期肺腺癌的临床研究  

Clinical study on Recombinant Human Endostatin Combined with Pemetrexed and Cisplatin on Advanced Lung Adenocarcinoma.

作　　者：李琪[1] 汪小鹏 杜文峰[1] Li Qi;Wang Xiaopeng;Du Wenfeng(Department of Pulmonology,Affiliated Puren Hospital of Wuhan University of Science and Technology,Hubei 430081,China)

机构地区：[1]武汉科技大学附属普仁医院呼吸内科,430081

出　　处：《医学研究杂志》2021年第4期78-81,共4页Journal of Medical Research

基　　金：武汉市卫生和计划生育委员会临床医学科研项目(WX17Z18)。

摘　　要：目的探讨晚期肺腺癌患者在培美曲塞和顺铂化疗基础上,联合重组人血管内皮抑制素治疗的效果及对相关肿瘤因子水平的影响。方法选择晚期肺腺癌患者95例,均为笔者医院2017年1月~2019年12月收治,采用培美曲塞、顺铂化疗(对照组,n=45)与培美曲塞、顺铂化疗基础上联合血管内皮抑制素治疗(实验组,n=50)在总有效率、总体健康状况、不良反应率、相关肿瘤因子水平等方面进行比较。结果实验组晚期肺腺癌患者治疗总有效率经评定为80%,对照组经评定为57.78%,差异有统计学意义(P<0.05)。两组完成治疗后,患者CA125、CA199、CEA、CYFRA21-1、NSE、TNF-α各指标检测值均有下降,且实验组相较对照组治疗后有更为明显的下降程度,差异有统计学意义(P<0.05)。两组在完成治疗后,总体健康状况评分值均有下降,但实验组较对照组降幅较小,差异有统计学意义(P<0.05)。实验组不良反应率低于对照组(P<0.05)。结论培美曲塞和顺铂化疗基础上联合重组人血管内皮抑制素治疗晚期肺腺癌,可提高总有效率,明显降低相关肿瘤因子水平,维持总体健康状况平稳,且具有更高的安全性。Objective To investigate the effect of pemetrexed and cisplatin combined with recombinant human endostatin in the treatment of advanced lung adenocarcinoma and its influence on the level of related tumor factors.Methods Totally 95 patients with advanced lung adenocarcinoma were selected from January 2017 to December 2019 in our hospital.They were divided into two groups:pemetrexed and cisplatin chemotherapy(control group,n=45)and pemetrexed and cisplatin combined with endostatin(experimental group,n=50).The control group was compared with the experimental group in terms of total effective rate,overall health status,adverse reaction rate and related tumor factor levels.Results The total effective rate was 80%in the experimental group and 57.78%in the control group(P<0.05).CA125,CA199,CEA,CYFRA21-1,NSE and TNF-αin the two groups were decreased after the treatment,and the experimental group had a more significant decline than the control group after treatment(P<0.05).The overall health status scores of the two groups were decreased after the treatment,but the decrease rate of the experimental group was smaller than that of the control group(P<0.05).The adverse reaction rate of the experimental group was lower than that of the control group(P<0.05).Conclusion Pemetrexed and cisplatin combined with recombinant human endostatin in treatment of patients with advanced lung adenocarcinoma can improve the total effective rate,significantly reduce the level of related tumor factors,maintain the overall health status,and have higher safety.

关 键 词：肺腺癌 重组人血管内皮抑制素 培美曲塞 顺铂 肿瘤因子 

分 类 号：R734.2[医药卫生—肿瘤]